Cargando…

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

Intramuscular (IM) administration of an adeno-associated viral (AAV) vector represents a simple and safe method of gene transfer for treatment of the X-linked bleeding disorder hemophilia B (factor IX, F.IX, deficiency). However, the approach is hampered by an increased risk of immune responses agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nayak, Sushrusha, Sarkar, Debalina, Perrin, George Q., Moghimi, Babak, Hoffman, Brad E., Zhou, Shangzhen, Byrne, Barry J., Herzog, Roland W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260742/ https://www.ncbi.nlm.nih.gov/pubmed/22279442 http://dx.doi.org/10.3389/fmicb.2011.00244

Ejemplares similares

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies
por: Markusic, David M, et al.
Publicado: (2013)

Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia
por: Sarkar, Debalina, et al.
Publicado: (2014)

Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity
por: Martino, Ashley T., et al.
Publicado: (2009)

Targeted approaches to induce immune tolerance for Pompe disease therapy
por: Doerfler, Phillip A, et al.
Publicado: (2016)

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
por: Haurigot, Virginia, et al.
Publicado: (2010)

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B
por: Rogers, Geoffrey L, et al.
Publicado: (2014)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
por: Miller, Connie H
Publicado: (2021)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
por: Herzog, Roland W., et al.
Publicado: (2017)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B
por: Xie, Chen, et al.
Publicado: (2019)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Gene Therapy Research at the Frontiers of Viral Immunology
por: Hoffman, Brad E., et al.
Publicado: (2012)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX
por: Ramaswamy, Suvasini, et al.
Publicado: (2018)

The Need for Gene Therapy for the Effective Treatment of Hemophilia
por: Wynn, Tung, et al.
Publicado: (2012)

CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs
por: Chen, Jiahuan, et al.
Publicado: (2020)

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience
por: Bouyadmar, Meryem, et al.
Publicado: (2022)

Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells
por: Wang, Xiaomei, et al.
Publicado: (2017)

Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice
por: Herzog, Roland W., et al.
Publicado: (2019)

Gallium-Protoporphyrin IX Inhibits Pseudomonas aeruginosa Growth by Targeting Cytochromes
por: Hijazi, Sarah, et al.
Publicado: (2017)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Riemerella anatipestifer Type IX Secretion System Is Required for Virulence and Gelatinase Secretion
por: Guo, Yunqing, et al.
Publicado: (2017)

Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs
por: Callan, Mary Beth, et al.
Publicado: (2016)

Salmonella Typhimurium Infection Leads to Colonization of the Mouse Brain and Is Not Completely Cured With Antibiotics
por: Chaudhuri, Debalina, et al.
Publicado: (2018)

Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
por: Larson, Emily A., et al.
Publicado: (2021)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

The Type IX Secretion System (T9SS): Highlights and Recent Insights into Its Structure and Function
por: Lasica, Anna M., et al.
Publicado: (2017)

Development of an AAV DNA-based synthetic vector for the potential gene therapy of hemophilia in children
por: Shoti, Jakob, et al.
Publicado: (2022)

Identification and Genetic Analysis of a Factor IX Gene Intron 3 Mutation in a Hemophilia B Pedigree in China
por: Cao, Dong-Hua, et al.
Publicado: (2014)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies
por: Al-Allaf, Faisal A., et al.
Publicado: (2017)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

Recombinant Production of Biliverdin IXβ and δ Isomers in the T7 Promoter Compatible Escherichia coli Nissle
por: Robinson, Elizabeth A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq5i5e1iii2e2r3jdk0rlndutr